Mark W. Surber, Ph.D.

Chairman, President and Chief Executive Officer

Mark W. Surber, Ph.D. is a serial entrepreneur and founder of Genoa Pharmaceuticals. At Genoa, Dr. Surber serves as Chairman, President and Chief Executive Officer and is the inventor of the GP-101 patent estate. Dr. Surber has over 20 years of pharmaceutical, diagnostic and device development experience, most of which has been spent starting and growing pharmaceutical companies.

Prior to Genoa, Dr. Surber served as a consultant providing multi-disciplinary drug development services to pharmaceutical companies. These included Elevation Pharmaceuticals and Cardeas Pharma, both developing inhaled products. Prior to consulting, Dr. Surber was the first employee at Aires Pharmaceuticals (acquired by Mast Therapeutics in 2014) where he was project lead and an inventor of Aironite, an inhaled medicine for treatment of pulmonary hypertension. Dr. Surber was also and first employee at Mpex Pharmaceuticals (acquired by Aptalis Pharma in 2011) where he held multiple positions of responsibility including project lead and inventor of Aeroquin/Quinsair, an inhaled medicine approved for the treatment of cystic fibrosis. Dr. Surber is well-published and holds multiple patents in formulation, drug delivery, pharmacology and pulmonary medicine. He has a Ph.D. in microbiology from the University of Illinois, and a M.S. and B.Sc. in microbiology from California State University, Long Beach.

Daniel D. Burgess

Member of Board of Directors

Daniel D. Burgess has served as a member of our board of directors since January, 2012. Mr. Burgess is a Venture Partner at SV Life Sciences. Prior to SV Life Sciences, Mr. Burgess was President of Rempex Pharmaceuticals, a company he co-founded in 2011 and subsequently sold to The Medicines Company in December 2013. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.

Michael J. Kamdar

Member of Board of Directors

Michael J. Kamdar has served as a Member of our Board of Directors since October 2011. Mr. Kamdar is currently a Strategic Advisor at Microdermis. Prior to this, Mr. Kamdar was President at Cellana. Prior to Cellana, Mr. Kamdar was founder, Chief Business Officer and Board Member at VentiRx Pharmaceuticals, which was optioned to Celgene Corporation in 2012. Over the past 20+ years, Mr. Kamdar has accounted for deal transactions in excess of $1.0B and raised over $350M from venture capital and public capital markets. Prior to VentiRx, Mr. Kamdar held several positions at Anadys Pharmaceuticals, most recently as SVP, Corporate Development and Finance including playing an instrumental role in the company's successful IPO. Prior to Anadys, Mr. Kamdar held several senior management positions at Agouron Pharmaceuticals, a Pfizer Company, most recently Vice President, Business Development. Additionally, Mr. Kamdar held various product management and new product planning positions at Hybritech, Inc., an Eli Lilly Company, and Centocor, Inc. Mr. Kamdar is a member of the Board of Directors of Tobira Therapeutics, Ciclofilin Pharmaceuticals, and Cellana. He received his B.S. in Biology from St. Joseph's University and his M.B.A. from Villanova University.